STREAMING NOW: Watch Now

Marijuana-derived drug for epilepsy gets FDA committee recommendation

A US Food and Drug Administration advisory committee on Thursday unanimously ...

Posted: Apr 19, 2018 5:44 PM
Updated: Apr 19, 2018 5:44 PM

A US Food and Drug Administration advisory committee on Thursday unanimously recommended approval of an epilepsy drug that would be the first plant-derived cannabidiol medicine for prescription use in the United States.

The FDA will vote in June whether to approve the drug, Epidiolex, an oral solution, for the treatment of severe forms of epilepsy in a small group of patients. The FDA has approved synthetic versions of some cannabinoid chemicals found in the marijuana plant for other purposes, including cancer pain relief.

Epidiolex is an oral solution of marijuana plant-derived cannabidiol

If approved by the FDA, the medicine will treat severe epilepsy syndromes

Cannabidiol, also called CBD, is one of more than 80 active cannabinoid chemicals, yet unlike tetrahydrocannabinol, or THC, it does not produce a high.

The committee's recommendation was delivered after reviewing data from the drug's maker, GW Pharmaceuticals PLC, a UK-based biopharmaceutical company.

Epidiolex, GW's lead cannabinoid product candidate, was developed for severe, early-onset epilepsy syndromes, including Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life; Lennox-Gastaut syndrome, a type of epilepsy with multiple types of seizures; and tuberous sclerosis complex and infantile spasms, both of which begin in infancy and cause a sudden stiffening of the body, arms and legs with the head bent forward.

One-third of Americans who have epilepsy have found no therapies that will control their seizures, according to the Epilepsy Foundation. This represents about 1 million families.

Though FDA approval would limit use of the drug to epilepsy patients, doctors would have the option to prescribe it "off-label" for other uses.

Shauna Garris, a pharmacist, pharmacy clinical specialist and adjunct assistant professor at the University of North Carolina's Eshelman School of Pharmacy, said she would be surprised if Epidiolex does not get full approval from the FDA. Garris was not involved in the development of the drug and has not used it in her own clinical practice.

Still, she said, "there's so much publicity and so much hype" surrounding the product, she's not sure it will live up to "all that hype."

Epidiolex is effective, she said, working somewhere between "fairly" and "very well."

"There have been side effects associated with it, and it appears a lot of the side effects were in conjunction with other medications, which is a concern, because most of those patients are on other medications," Garris said. There are likely to be drug interactions, she said, but "that's not uncommon for antiepileptic medications."

"Most of our antiepileptic medications have terrible side effects and interact with each other," she said. Still, this may impact potential efficacy.

In a statement, GW Pharmaceuticals said that two experimental clinical trials, one in Dravet syndrome and one in Lennox-Gastaut syndrome, showed "significantly greater reductions" in certain seizure types for patients taking Epidiolex compared with those taking a placebo.

During the public hearing at Thursday's advisory committee meeting, 16-year-old Sam Vogelstein of Berkeley, California, described himself as "the first person to try Epidiolex for epilepsy." He said he was not paid by the company to speak Thursday.

"I had seizures for 10 years," he said. "My parents tell me there were times I had seizures 100 times a day." He began Epidiolex five years ago. "I've been seizure-free for more than two years now. It changed my life."

Damage to the liver, which metabolizes drugs and detoxifies chemicals, is an important consideration during the recommendation process of any medicine.

Dr. Lara Dimick-Santos, a clinical reviewer in the FDA's Office of Drug Evaluation, reviewed the liver safety report and concluded that there were "no cases of severe liver injury" and "no deaths related with liver injury." She suggested, though, that some patients might experience some form of "unknown of chronic liver injury." Such a "smoldering inflammatory response" could "potentially cause a problem for patients further down the line."

Katherine Bonson, a member of the FDA's Pharmacologist Controlled Substance Staff, assessed the abuse potential for cannabidiol after looking at both animal and human experimental data. "Overall conclusion, preclinical data do not provide signals that CBD has abuse potential," she said.

Minnesota Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 95659

Reported Deaths: 2056
CountyConfirmedDeaths
Hennepin26960930
Ramsey10911320
Dakota7524126
Anoka6092133
Stearns401024
Washington379955
Scott257433
Olmsted244628
Nobles197116
Blue Earth16996
Wright16327
St. Louis160241
Carver14197
Clay138940
Rice13358
Mower13285
Sherburne115014
Kandiyohi10112
Winona88718
Lyon6954
Waseca6698
Benton5523
Steele5472
Freeborn5424
Nicollet54016
Watonwan5284
Crow Wing51618
Todd4952
Chisago4941
McLeod4882
Le Sueur4674
Otter Tail4414
Beltrami4215
Martin40810
Goodhue3659
Itasca32814
Pine3280
Douglas3102
Polk3054
Isanti2971
Becker2802
Carlton2701
Morrison2492
Dodge2390
Cottonwood2250
Pipestone22510
Chippewa2141
Meeker2022
Wabasha1960
Sibley1923
Brown1912
Yellow Medicine1822
Cass1804
Rock1730
Unassigned17052
Redwood1673
Mille Lacs1643
Murray1642
Renville1518
Jackson1481
Faribault1450
Swift1381
Houston1280
Kanabec1258
Roseau1230
Koochiching1223
Fillmore1200
Pennington1191
Lincoln1110
Hubbard1031
Stevens1031
Pope940
Big Stone820
Aitkin801
Wadena690
Wilkin653
Grant614
Lake590
Lac qui Parle581
Norman540
Marshall521
Mahnomen481
Red Lake451
Traverse310
Clearwater270
Lake of the Woods221
Kittson120
Cook60

Iowa Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 85533

Reported Deaths: 1305
CountyConfirmedDeaths
Polk15872262
Woodbury544764
Johnson512627
Black Hawk448990
Linn4010111
Story344417
Dubuque325741
Scott301128
Dallas278538
Pottawattamie211338
Buena Vista199112
Marshall178434
Sioux16183
Wapello133357
Webster125514
Plymouth114121
Clinton112121
Muscatine110855
Crawford10885
Cerro Gordo105721
Warren9566
Jasper83832
Des Moines7848
Marion7637
Henry7434
Tama71331
Carroll6625
Lee6377
Wright5811
Dickinson5276
Boone5078
Bremer4927
Washington45911
Louisa42915
Mahaska41219
Delaware4023
Floyd3493
Jackson3493
Franklin34818
Winneshiek3356
Clay3264
Lyon3264
Hamilton3223
Benton3101
Winnebago30313
Hardin2991
Poweshiek2958
Buchanan2791
Jones2743
Butler2702
Kossuth2700
Shelby2671
Clarke2653
Emmet26510
Allamakee2616
Clayton2523
Chickasaw2500
Sac2500
Cherokee2492
Cedar2461
Guthrie2456
Fayette2222
Harrison2223
Grundy2203
Madison2192
Iowa2091
Palo Alto2020
Humboldt1903
Mitchell1900
Howard1886
Hancock1842
Calhoun1833
Mills1801
Page1700
Cass1682
Osceola1610
Monroe15911
Pocahontas1592
Lucas1566
Monona1531
Jefferson1381
Appanoose1363
Union1353
Taylor1301
Davis1244
Ida1221
Fremont1180
Van Buren1141
Keokuk1091
Worth1080
Greene1010
Montgomery965
Wayne862
Audubon821
Adair721
Decatur670
Ringgold502
Adams330
Unassigned170
Rochester
Broken Clouds
61° wxIcon
Hi: 65° Lo: 45°
Feels Like: 61°
Mason City
Clear
65° wxIcon
Hi: 66° Lo: 47°
Feels Like: 65°
Albert Lea
Scattered Clouds
63° wxIcon
Hi: 64° Lo: 46°
Feels Like: 63°
Austin
Scattered Clouds
64° wxIcon
Hi: 65° Lo: 46°
Feels Like: 64°
Charles City
Clear
63° wxIcon
Hi: 65° Lo: 47°
Feels Like: 63°
Much Cooler Week Ahead
KIMT Radar
KIMT Eye in the sky

Community Events